Tebentafusp-tebn
Tebentafusp-tebn is a Bispecific T-cell Engager (BiTE) immunotherapy that targets the HLA-A*02:01/gp100 complex frequently found on uveal melanoma tumor cells and melanocytes.
It is the first FDA-approved treatment indicated for use in unresectable or metastatic uveal melanoma in patients who are HLA-A*02:01-positive.
Provider Resources
